FDA accepts Bayer’s application to expand NUBEQA’s use in prostate cancer treatment

The U.S. Food and Drug Administration (FDA) has accepted Bayer’s supplemental new drug application (sNDA) for NUBEQA (darolutamide), potentially broadening its use for patients with ... Read More